Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2025)
Autolus Therapeutics posted quarterly Cost of Revenue of $25.3 million for Q4 2025, up 122.45% year-on-year from $11.4 million in Q4 2024, and down 11.57% on a QoQ basis from $28.6 million in Q3 2025.
Autolus Therapeutics (AUTL) has 2 years of Cost of Revenue data on file, last reported at $25.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue rose 122.45% year-over-year to $25.3 million; the trailing twelve-month figure through Dec 2025 stood at $96.4 million (up 746.31% YoY), and the FY2025 full-year result was $96.4 million, up 746.31% from the prior year.
- Cost of Revenue for Q4 2025 stood at $25.3 million, down from $28.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $28.6 million in Q3 2025 and bottomed at $11.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 296.00 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | 25.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.33 Mn |
| Dec 31, 2025 | 25.33 Mn |
| Sep 30, 2025 | 28.64 Mn |
| Sep 30, 2025 | 28.64 Mn |
| Jun 30, 2025 | 24.45 Mn |
| Jun 30, 2025 | 24.45 Mn |
| Mar 31, 2025 | 17.95 Mn |
| Mar 31, 2025 | 17.95 Mn |
| Dec 31, 2024 | 11.39 Mn |
| Dec 31, 2024 | 11.39 Mn |